Screener
Rhythm Pharmaceuticals, Inc. RYTM Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Interest income | 3,554 | 3,639 |
| Total other income (expense), net | (2,733) | (2,414) |
| Loss before income taxes | (55,094) | (49,418) |
| Provision for income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
| Accrued dividends on convertible preferred stock | (1,104) | (1,322) |
| Net loss attributable to common stockholders | $(56,743) | $(50,820) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.83) | $(0.81) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s income tax?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported income tax of $545K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s income tax changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s income tax increased by 581.3% year-over-year, from $80K to $545K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude